Pembrolizumab biosimilar (Amgen)

帕博利珠单抗生物类似药 (安进)

Report date: 2026/05/07 20:00:36

Base Information

Drug NamePembrolizumab biosimilar (Amgen)

Drug Alias NameABP 234ABP-234

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBulgariaUnited StatesTaiwan +[24]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

ATC CodeL01FF02L01XC18